# BeOne Medicines Ltd.
# 百濟神州有限公司

*(formerly known as BeiGene, Ltd. 百濟神州有限公司)*
*(incorporated in the Cayman Islands with limited liability and continued in Switzerland)*
**(Stock Code: 06160)**

## (1) CHANGE OF DOMICILE AND CONTINUATION;
## (2) ADOPTION OF PROPOSED SWISS ARTICLES;
## (3) APPOINTMENT OF SWISS AUDITOR; AND
## (4) CHANGE OF ENGLISH NAME, COMPANY WEBSITE AND COMPANY LOGO

References are made to (i) the announcement of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) (the "**Company**") dated August 7, 2024 in respect of, among other things, the proposed change of domicile and Continuation and the proposed Adoption of Proposed Swiss Articles; (ii) the announcement of the Company dated November 14, 2024 in respect of the Proposed Change of English Name of Company; (iii) the circular (the "**Circular**") of the EGM of the Company filed with the HKEx on March 10, 2025; and (iv) the announcement of the Company dated April 29, 2025 in respect of the poll results of the EGM (together with the announcements referred to in (i) and (ii), collectively as the "**Announcements**").

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the Circular and the Announcements.

### CHANGE OF DOMICILE AND CONTINUATION

The Company is pleased to announce that the Company's Continuation to Switzerland as a stock corporation under the laws of Switzerland became effective on May 27, 2025 (Swiss time).

With effect from the Continuation becoming effective, (i) the registered office of the Company has been changed to c/o BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel, Switzerland; and (ii) Computershare Switzerland Ltd at Baslerstrasse 90, P.O. Box, 4601 Olten, Switzerland has been appointed as the principal share registrar and transfer office of the Company in Switzerland. Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong remains as the branch share registrar and transfer office of the Company in Hong Kong.

### ADOPTION OF PROPOSED SWISS ARTICLES

With effect from the Continuation becoming effective, the Proposed Swiss Articles, as approved and adopted pursuant to the passing of a special resolution by the Shareholders at the EGM, became effective on May 27, 2025 (Swiss time).

## APPOINTMENT OF SWISS AUDITOR

With effect from the Continuation becoming effective, as approved pursuant to the passing of an ordinary resolution by the Shareholders at the EGM, the appointment of Ernst & Young AG, Switzerland as the Swiss statutory auditor of the Company (for Swiss legal purposes) to hold office until the next annual general meeting of the Company, to provide audit services in accordance with the requirements under Swiss law, including in connection with the Continuation, became effective on May 27, 2025 (Swiss time).

Upon the Continuation, (a) Ernst & Young LLP, located in Boston, Massachusetts, United States, will continue to be the Company's independent registered accounting firm for the audits of the Company's financial statements to be filed with the SEC; (b) Ernst & Young, located in Hong Kong, the PRC, will continue to be the Company's reporting accounting firm for the audit of the Company's financial statements to be filed with the HKEx; and (c) Ernst & Young Hua Ming LLP, located in Beijing, PRC, will continue to be the Company's reporting accounting firm for the audit of the Company's financial statements to be filed with the Shanghai Stock Exchange.

## CHANGE OF ENGLISH NAME OF COMPANY

The Company is pleased to announce that subsequent to the Adoption of the Proposed Swiss Articles, which incorporated the new English name of the Company of "BeOne Medicines Ltd.", being approved and adopted pursuant to the passing of a special resolution by the Shareholders at the EGM held on April 28, 2025, the new English name of the Company became effective on May 27, 2025 (Swiss Time). Accordingly, the English name of the Company has changed from "BeiGene, Ltd." to "BeOne Medicines Ltd." (the "**Change of English Name of the Company**"), with effect from May 27, 2025 (Swiss Time).

The Chinese name of the Company will remain unchanged. The stock code of the Company on the HKEx will remain unchanged as "06160".

Following the Change of English Name of the Company and subject to the confirmation of the HKEx, the English stock short name for trading in the Shares on the HKEx is expected to be changed. The Company will make further announcement(s) in relation to the expected timetable as soon as practicable to keep the Shareholders and potential investors informed.

## CHANGE OF COMPANY WEBSITE

The website of the Company has been changed from "www.beigene.com" to "www.beonemedicines.com" with effect from May 27, 2025 (Swiss Time). All announcements, notices or other documents submitted by the Company for publication on the website of the HKEx will also be published on this new website of the Company. The Investor Relations e-mail of the Company has been changed from "ir@beigene.com" to "ir@beonemed.com".

## CHANGE OF COMPANY LOGO

In light of the Change of English Name of the Company, the Company has adopted the following logo with effect from May 27, 2025 (Swiss Time).

## EFFECTS ON THE CHANGE OF ENGLISH NAME OF COMPANY

The Change of English Name of the Company will not affect any of the rights of the Shareholders.

All existing certificates of Shares (in blue) in issue bearing the former English name of the Company will, after the Change of English Name of the Company, continue to be evidence of legal title to such shares and valid for trading, settlement, registration and delivery purposes. Following the Change of English Name of the Company becoming effective, new share certificates (also in blue) will be issued in the new English name of the Company. There will not be any arrangement for exchange of existing certificates of securities for new certificates bearing the new English name of the Company.

By order of the Board
**BeOne Medicines Ltd.**
**Mr. John V. Oyler**
*Chairman*

Hong Kong, May 27, 2025

*As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.*